Grace Therapeutics, Inc. (GRCE) Form S-3 — Aug 24, 2026
Grace Therapeutics filed a Form S-3 registering the resale of up to 4,761,904 shares of common stock by selling stockholders, satisfying its registration rights agreement dated August 4, 2026 tied to a private placement that closed August 6, 2026 at $2.10 per share. The company will receive no proceeds from any resale and retains none of the offering economics. The registered shares represent roughly 22.6 percent of the 21,035,930 shares outstanding as of August 11, 2026, a sizable potential overhang for a micro-cap. The stock last traded at $2.20 on Nasdaq on August 21, 2026, and the underlying private placement generated net proceeds of approximately $9.1 million for the company.
Key figures
- Offering Price
- $2.10 per share (private placement purchase price); last reported market price $2.20 on August 21, 2026
- Shares Offered
- 4761904
- Shares Outstanding
- 21035930
- Pipe Net Proceeds
- approximately $9.1 million
- Sec Registration Fee
- $1,446.76
- Granted And Pending Patents
- more than 79
- Max Aggregate Offering Price
- $10,476,188.80
- Private Placement Close Date
- August 6, 2026
- Estimated Nda Fee Savings GTx104
- $4.3 million
- Total Estimated Offering Expenses
- $81,446.76
- Percent Of Shares Outstanding Registered
- 22.6%
Price after filing
Close on the filing date to close N calendar days later (from $2.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.